These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 39101772)

  • 1. Combining iRGD with HuFOLactis enhances antitumor potency by facilitating immune cell infiltration and activation.
    Shao J; Xin K; Qian Z; Liu F; Li L; Zhu J; Liu Q; Tian M; Liu B
    Hum Vaccin Immunother; 2024 Dec; 20(1):2375825. PubMed ID: 39101772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
    Zhou S; Meng F; Du S; Qian H; Ding N; Sha H; Zhu M; Yu X; Wang L; Liu B; Wei J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma.
    Dong Y; Huang Y; Zhang Z; Chen A; Li L; Tian M; Shen J; Shao J
    J Transl Med; 2023 Mar; 21(1):205. PubMed ID: 36932395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells.
    Zhu M; Wang H; Zhou S; Wei J; Ding N; Shao J; Yu L; Feng Z; Liu B
    Onco Targets Ther; 2021; 14():835-844. PubMed ID: 33574677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose radiotherapy synergizes with iRGD-antiCD3-modified T cells by facilitating T cell infiltration.
    Zhou S; Zhu M; Wei X; Mu P; Shen L; Wang Y; Wan J; Zhang H; Xia F; Zhang Z
    Radiother Oncol; 2024 May; 194():110213. PubMed ID: 38458258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
    Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
    J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy.
    Song Y; Xu M; Li Y; Li Y; Gu W; Halimu G; Fu X; Zhang H; Zhang C
    Int J Pharm; 2020 Aug; 586():119498. PubMed ID: 32505575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer.
    Ding N; Zou Z; Sha H; Su S; Qian H; Meng F; Chen F; Du S; Zhou S; Chen H; Zhang L; Yang J; Wei J; Liu B
    Nat Commun; 2019 Mar; 10(1):1336. PubMed ID: 30902997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement.
    Pan Y; Xue Q; Yang Y; Shi T; Wang H; Song X; Luo Y; Liu W; Ren S; Cai Y; Nie Y; Song Z; Liu B; Li JP; Wei J
    Cell Rep Med; 2024 Jun; 5(6):101590. PubMed ID: 38843844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer.
    Wang F; Li B; Fu P; Li Q; Zheng H; Lao X
    Int J Pharm; 2018 Aug; 547(1-2):611-620. PubMed ID: 29933059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer.
    Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J
    Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tumor-penetrating recombinant protein anti-EGFR-iRGD enhance efficacy of paclitaxel in 3D multicellular spheroids and gastric cancer in vivo.
    Sha H; Li R; Bian X; Liu Q; Xie C; Xin X; Kong W; Qian X; Jiang X; Hu W; Liu B
    Eur J Pharm Sci; 2015 Sep; 77():60-72. PubMed ID: 25998561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy.
    Zhu J; Ke Y; Liu Q; Yang J; Liu F; Xu R; Zhou H; Chen A; Xiao J; Meng F; Yu L; Li R; Wei J; Liu B
    Nat Commun; 2022 Dec; 13(1):7466. PubMed ID: 36463242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment.
    Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B
    Sci Rep; 2017 Apr; 7(1):579. PubMed ID: 28373646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.
    Zhong Y; Su T; Shi Q; Feng Y; Tao Z; Huang Q; Li L; Hu L; Li S; Tan H; Liu S; Yang H
    Int J Nanomedicine; 2019; 14():8543-8560. PubMed ID: 31802868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide iRGD Against Gastric Cancer.
    Zhang D; Chu Y; Qian H; Qian L; Shao J; Xu Q; Yu L; Li R; Zhang Q; Wu F; Liu B; Liu Q
    Int J Nanomedicine; 2020; 15():735-747. PubMed ID: 32099362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment.
    Zhang Z; Qian H; Huang J; Sha H; Zhang H; Yu L; Liu B; Hua D; Qian X
    Int J Nanomedicine; 2018; 13():4961-4975. PubMed ID: 30214200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy.
    Deng C; Jia M; Wei G; Tan T; Fu Y; Gao H; Sun X; Zhang Q; Gong T; Zhang Z
    Mol Pharm; 2017 Jan; 14(1):296-309. PubMed ID: 27936775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.